Description of Thymosin Alpha-1
Thymosin Alpha-1, a naturally occurring peptide in the thymus, is recognized for modulating immune functions and responses. It has been investigated in research related to morbidity and mortality in sepsis and various infections. Studies suggest its potential research interest in the context of severely ill COVID-19 patients, particularly in relation to lymphocytic immunity and T cell activation. Thymosin Alpha-1, and its analogues exhibit immune-modulating properties, inducing cytokine production, lymphocyte differentiation, and influencing macrophage function. They act via Toll-like receptor activation in dendritic cells, with potential relevance to cytokine storm responses induced by SARS-CoV-2 infection. Clinical studies have examined their activity in various diseases, including viral infections and cancers. In COVID-19 research, Thymosin Alpha-1 has been investigated in the context of mortality indicators and immune function. Further research is warranted to explore its potential as a research compound or adjunctive subject of study to investigate disease severity. Now we would like to bring you closer to the effects of the peptide confirmed in several research studies.
[1]
Overview of Published Research
1. Thymosin Alpha-1 In Immune Modulation
Thymosin Alpha-1 (Tα1) is a potent immunomodulator with pleiotropic effects on various immune cell subsets. The thymus is responsible for T-cells, which are the most important parts of the adaptive immune system, and help the immune system remember past infections and improve the function. The peptide works at a fundamental level of the immune system, activating signaling pathways and stimulating the production of cytokines. Acting through Toll-like receptors in dendritic cells, Thymosin Alpha-1 stimulates the production of immune-related cytokines, making it a subject of research interest in the context of immune suppression associated with aging, infection, or cancer. Extensive preclinical and clinical studies have examined Tα1's influence on immune system function and its research potential in diverse diseases.
Combining Thymosin Alpha-1 (Tα1) with bursin-like peptide (BLP) as a recombinant fusion peptide (Tα1-BLP) has been studied for its influence on immune responses against avian influenza. This novel adjuvant was observed to affect antibody titers, Th1- and Th2-type cytokine secretion, lymphocyte proliferation, and provided effects against virus replication and lung damage in the studied models. The study underscores Tα1-BLP's potential as a research subject for avian influenza vaccines, highlighting its immunopotentiating properties and immune-related effects.
Furthermore, in subjects with sepsis, a life-threatening condition characterized by dysregulated immune response to infection, Thymosin Alpha-1 (Tα1) shows research promise as an adjunctive compound. Clinical studies indicate that Tα1 administration, alone or in combination with anti-inflammatory agents, was associated with changes in mortality rates, immune function indicators, and incidence of secondary infections. However, the heterogeneous nature of sepsis poses challenges in generalizing clinical results, and future trials focusing on immunosuppressed individuals may provide further insights into Tα1's activity in the context of sepsis.
[2] - [4]
2. Thymosin Alpha-1 In Nerve Growth
The immune system plays an important role also in CNS nerve growth and development. Thymosin Alpha-1 has been found to significantly impact neurodevelopment in mice following peripheral administration, with observed changes in cognitive function indicators. Studies suggest that this peptide influences gene expression related to neuron growth and connectivity, affecting an environment associated with neurological development. Additionally, Thymosin Alpha-1 has been observed to influence inflammation and dysfunction within the nervous system, with associated changes in brain structure and function markers in the studied models.
In neonatal mice, administration of Thymosin Alpha-1 (Tα1) was associated with changes in cognitive indicators and neurogenesis in the hippocampus. This effect was accompanied by increased levels of neurotrophic factors such as interleukin-4, interferon-gamma, brain-derived neurotrophic factor, nerve growth factor, and insulin-like growth factor-1, along with a reduction in inflammatory cytokines like IL-6 and tumor necrosis factor-α. Tα1 induces a Th1-polarized immune response and was observed to influence lipopolysaccharide-induced changes in hippocampal neurogenesis, suggesting potential neuroprotective properties relevant to research into infections.
[5]
3. Thymosin Alpha-1 and Its Anti-Fungal Properties
Thymosin Alpha-1 (Tα1) emerges as a research subject of interest in activating dendritic cells (DCs) against fungal infections, particularly in response to Aspergillus fumigatus. Dendritic cells are a specific type of cell in the immune system, are important in helping the immune system to recognize fungal infections. Through the p38 mitogen-activated protein kinase/nuclear factor (NF)-kappaB-dependent pathway, Tα1 induces maturation and interleukin-12 production in fungus-pulsed DCs, facilitated by toll-like receptor (TLR) signaling via the myeloid differentiation factor 88 (MyD88)-dependent pathway. This activation was associated with Th1-dependent antifungal immunity in vivo, with observed effects on myeloid cell recovery and aspergillosis indicators, particularly in highly susceptible individuals such as those receiving hematopoietic transplants.
Furthermore, Tα1, initially characterized for its diverse effects on the immune system, is now recognised as a key regulator of inflammation, immunity, and tolerance. Its role in modulating DC function underscores its research potential in inducing various forms of immunity and tolerance. Recent findings reveal Tα1's ability to influence DCs for antifungal Th1 resistance, activate plasmacytoid DCs (pDCs) via TLR9/MyD88-dependent viral recognition, and induce indoleamine 2,3-dioxygenase activity, influencing tolerance towards self and microbial antigens. This regulation of immune homeostasis positions Tα1 as a promising research candidate in the context of leveraging DCs and tryptophan catabolism to study inflammation, immunity, and tolerance across diverse research contexts.
[6], [7]
4. Thymosin Alpha-1 in Hepatitis
Thymosin Alpha-1 (Tα1), initially investigated in the context of hepatitis B and C, is now gaining recognition for its potential across a spectrum of diseases. Approved in numerous countries, for example currently approved in the context of hepatitis B and C in over 35 different developing countries, Tα1 is undergoing late-stage clinical trials in the US and Europe for hepatitis C and stage IV melanoma. Recent trials suggest broader research applications, including septic shock, acute respiratory distress syndrome, peritonitis, acute cytomegalovirus infection, tuberculosis, severe acute respiratory syndrome, and lung infections in critically ill patients. Additionally, Tα1 shows research promise as a chemoprotection subject during chemotherapy, indicating its emerging relevance in the investigation of life-threatening and chronic diseases.
[8]
5. Thymosin Alpha-1 and HIV
Thymosin Alpha-1 (Tα1) represents a research avenue of interest for investigating immune reconstitution in HIV-1-infected individuals undergoing antiretroviral therapy. Despite the observed effects of antiretroviral therapy, complete immune restoration remains elusive, often accompanied by persistent inflammation and inadequate cytotoxic T-cell responses. Tα1, known for its observed capacity to influence immune homeostasis in various conditions, including infections and immunodeficiency, holds potential as a multitasking research compound depending on the host's inflammatory or immune status. Recent in vitro and in vivo studies have examined Tα1's activity in HIV-1 infection, offering insights into its research implications and future directions for investigation.
Furthermore, Tα1 demonstrates the capacity to influence the release of antiretroviral soluble factors by CD8(+) cells, contributing to the study of HIV-1 infection control through non-cytolytic mechanisms. Through its specific action on lymphoid cells, Tα1 induces a robust transcriptional response, influencing the release of soluble factors that were observed to inhibit HIV-1 infection of monocyte-derived macrophages and peripheral blood mononuclear cells (PBMCs), as well as human T lymphotropic virus 1 (HTLV-1) infection of PBMCs. These findings underscore the potential of Tα1 as a subject of research interest alongside innovative study approaches and vaccine research strategies in the investigation of HIV-1 infection.
[9], [10]
6. Thymosin Alpha-1 As An ACE Enzyme Inhibitor
The research investigated the antioxidant properties of thymosin alpha-1 (Tα1) peptide using various methods. Research indicates that Thymosin Alpha-1 may inhibit angiotensin converting enzyme (ACE) and thus may influence blood pressure in research models. Tα1 demonstrated significant scavenging activity against DPPH and ABTS radicals, with IC50 values of 20 µM and 85 µM, respectively. Additionally, it exhibited concentration-dependent scavenging of hydroxyl and superoxide radicals, with IC50 values of 82 µM and 20 µM, respectively. Tα1 also reduced cellular reactive oxygen species (ROS) levels in human neural asterocytoma cells. Furthermore, Tα1 displayed inhibitory effects on angiotensin-converting enzyme (ACE), with a mixed inhibition pattern observed in kinetic studies. The IC50 and Ki values of Tα1 were 0.8 µM and 3.33 µM, respectively. Molecular modeling and docking analyses suggested that Tα1 binds to ACE domains, particularly the N-domain, with high affinity, mediated by electrostatic, hydrophobic, and hydrogen forces. Overall, these findings highlight Tα1 as a multifunctional peptide with dual antioxidant and ACE-inhibitory properties, warranting further investigation of its potential both in vitro and in vivo.
[11]
7. Thymosin Alpha-1 in Cancer Research
Thymosin Alpha-1 has been investigated and is undergoing active investigation in a number of different cancer research contexts. Thymosin alpha-1 (Thα1) demonstrates anti-proliferative effects on lung adenocarcinoma cells (A549), inhibiting cell growth and migration while influencing antioxidant enzyme activity and reducing cellular reactive oxygen species (ROS) levels. However, it does not significantly induce apoptosis in these cells. In a large randomized study, combining Thα1 with dacarbazine (DTIC) and interferon alfa (IFN-alpha) in patients with metastatic melanoma showed notable findings. Patients receiving the combination showed tumor responses and longer duration of response compared to the control group receiving standard approaches alone. Median overall survival (OS) showed differences with Thα1 administration, suggesting its research interest in the context of metastatic melanoma. Clinical trials have provided findings supporting the investigation of Thα1 in melanoma research, particularly in combination with other agents like DTIC and IFN-alpha, informing further evaluation of Thα1 in melanoma research.
Two studies investigated the development and activity of a novel long-acting fusion protein called Thymosin Alpha1-Fc (Tα1-Fc) in the context of breast cancer research. The first study focused on generating Tα1-Fc by fusing Tα1 with the Fc domain of human IgG1 to improve its serum half-life. Tα1-Fc demonstrated enhanced activity in influencing the growth of 4T1 and MCF-7 breast cancer cells compared to native Tα1. In a murine 4T1 tumor model, Tα1-Fc administration led to increased levels of CD4 and CD8 cells, interferon-γ, and interleukin-2, indicating changes in immune response against tumors. Moreover, Tα1-Fc influenced immunosuppression induced by hydrocortisone, suggesting its potential as an immunomodulatory research compound in the context of breast cancer.
In the second study, a recombinant plasmid was constructed to express Tα1-Fc fusion protein, utilizing the Fc domain of human IgG4. The optimised expression conditions yielded high-purity Tα1-Fc protein with a production rate of 160.4 mg/L. Tα1-Fc exhibited a prolonged serum half-life of 25 h in mouse models, approximately 13 times longer than native Tα1. Additionally, Tα1-Fc demonstrated changes in immune injury markers by influencing lymphocyte numbers. In vivo, Tα1-Fc displayed more pronounced antitumor activity in 4T1 and B16F10 tumor xenograft models compared to native Tα1. It upregulated CD86 expression, promoted secretion of IFN-γ and IL-2, and increased the number of tumor-infiltrating CD4+ T and CD8+ T cells. These findings highlight the potential of Tα1-Fc as a research compound in the context of breast cancer immunotherapy, providing insights for the development of novel cancer immunotherapy research approaches.
[12] - [16]
8. Thymosin Alpha-1 in Inflammatory Pain Research
Thymosin Alpha-1 (Tα1) displays anti-inflammatory and neuroprotective properties in research models, though its effects on inflammatory pain remain an area of ongoing investigation. Intraperitoneal administration of Tα1 was observed to influence pain hypersensitivity induced by Complete Freund's Adjuvant (CFA), a model of peripheral inflammation. This administration was also associated with changes in the up-regulation of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in both inflamed skin and the spinal cord. Moreover, Tα1 influenced the activation of microglia triggered by CFA-induced peripheral inflammation and modulated the expression of vesicular glutamate transporter (VGLUT) and vesicular γ-aminobutyric acid transporter (VGAT) in the spinal cord. These findings suggest that Tα1 may be of research interest in the context of inflammatory pain through its influence on microglia-induced pro-inflammatory cytokine production and VGLUT and VGAT expression in the spinal cord.
[17]
9. Thymosin Alpha-1 and Damaged Teeth
The review compares interventions for managing traumatised permanent teeth with avulsion injuries, analyzing three randomized controlled trials (RCTs). Study one examined the effect of extra-oral endodontics, showing no significant difference in radiographic resorption compared to intra-oral endodontics provided at week 1 for teeth avulsed for more than 60 minutes dry time. Study two investigated a 10-minute soaking in Thymosin Alpha-1 prior to replantation and reported notable findings at 48 months. Study three investigated a 20-minute soaking with gentamycin sulphate prior to replantation and the use of hyperbaric oxygen daily, showing notable findings at 12 months. Despite moderate/high risk of bias in these studies, they suggest potential areas of interest for Thymosin Alpha-1 and gentamycin sulphate followed by hyperbaric oxygen research. However, further validation and evidence with low risk of bias are needed.
[19]
10. Synthesis of Thymosin Alpha-1
In the development of Thymosin-α1, an acetylated 28 amino acid long research peptide, the synthesis via conventional chemical methods is challenging. A fully convergent chemo-enzymatic peptide synthesis (CEPS) process was developed, using a substrate-tailored peptiligase variant called thymoligase. Thymoligase, tailored to recognize 14-mer Thymosin-α1 segments, catalyzes peptide bond formation between segments with high efficiency (>94% yield). The crystal structure of thymoligase was determined, showing good agreement with the engineering model. This combination of solid-phase peptide synthesis (SPPS) of 14-mer segments and thymoligase-catalyzed ligation resulted in a significantly increased overall yield (55%) of Thymosin-α1 compared to existing industrial processes.
[20]
References
- A. Dominari at al., "Thymosin alpha 1: A comprehensive review of the literature", 2020 Dec 15; 9(5): 67–78.
- R. King and C. Tuthill, "Immune Modulation with Thymosin Alpha 1 Treatment," Vitam. Horm., vol. 102, pp. 151–178, 2016.
- C. Zhang, J. Zhou, K. Cai, W. Zhang, C. Liao, and C. Wang, "Gene cloning, expression and immune adjuvant properties of the recombinant fusion peptide Tα1-BLP on avian influenza inactivate virus vaccine," Microb. Pathog., vol. 120, pp. 147–154, Jul. 2018.
- F. Pei, X. Guan, and J. Wu, "Thymosin alpha 1 treatment for patients with sepsis," Expert Opin. Biol. Ther., vol. 18, no. sup1, pp. 71–76, 2018.
- G. Wang et al., "Immunopotentiator Thymosin Alpha-1 Promotes Neurogenesis and Cognition in the Developing Mouse via a Systemic Th1 Bias," Neurosci. Bull., vol. 33, no. 6, pp. 675–684, Dec. 2017.
- L. Romani et al., "Thymosin α 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling," Blood, vol. 103, no. 11, pp. 4232–4239, Jun. 2004.
- L. Romani et al., "Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance," Ann. N. Y. Acad. Sci., vol. 1112, pp. 326–338, Sep. 2007.
- A. L. Goldstein and A. L. Goldstein, "From lab to bedside: emerging clinical applications of thymosin alpha 1," Expert Opin. Biol. Ther., vol. 9, no. 5, pp. 593–608, May 2009.
- C. Matteucci et al., "Thymosin alpha 1 and HIV-1: recent advances and future perspectives," Future Microbiol., vol. 12, pp. 141–155, 2017.
- C. Matteucci et al., "Thymosin α 1 potentiates the release by CD8(+) cells of soluble factors able to inhibit HIV-1 and human T lymphotropic virus 1 infection in vitro," Expert Opin. Biol. Ther., vol. 15 Suppl 1, pp. S83-100, 2015.
- J. Kharazmi-Khorassani, A. Asoodeh, and H. Tanzadehpanah, "Antioxidant and angiotensin-converting enzyme (ACE) inhibitory activity of thymosin alpha-1 (Thα1) peptide," Bioorganic Chem., vol. 87, pp. 743–752, Jun. 2019.
- J. Kharazmi-Khorassani and A. Asoodeh, "Thymosin alpha-1; a natural peptide inhibits cellular proliferation, cell migration, the level of reactive oxygen species and promotes the activity of antioxidant enzymes in human lung epithelial adenocarcinoma cell line (A549)," Environ. Toxicol., May 2019.
- M. Maio et al., "Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma," J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 28, no. 10, pp. 1780–1787, Apr. 2010.
- R. Danielli, E. Fonsatti, L. Calabrò, A. M. Di Giacomo, and M. Maio, "Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond," Ann. N. Y. Acad. Sci., vol. 1270, pp. 8–12, Oct. 2012.
- X. Shen et al., "Generation of a novel long-acting thymosin alpha1-Fc fusion protein and its efficacy for the inhibition of breast cancer in vivo," Biomed. Pharmacother. Biomedecine Pharmacother., vol. 108, pp. 610–617, Dec. 2018.
- F. Wang, T. Yu, H. Zheng, and X. Lao, "Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life," Sci. Rep., vol. 8, no. 1, p. 12351, Aug. 2018.
- Y. Xu et al., "Thymosin Alpha-1 Inhibits Complete Freund's Adjuvant-Induced Pain and Production of Microglia-Mediated Pro-inflammatory Cytokines in Spinal Cord," Neurosci. Bull., Feb. 2019.
- L. Romani et al., "Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis," Nat. Med., vol. 23, no. 5, pp. 590–600, May 2017.
- P. F. Day, M. Duggal, and H. Nazzal, "Interventions for treating traumatised permanent front teeth: avulsed (knocked out) and replanted," Cochrane Database Syst. Rev., vol. 2, p. CD006542, 05 2019.
- M. Schmidt et al., "Design of a substrate-tailored peptiligase variant for the efficient synthesis of thymosin-α1," Org. Biomol. Chem., vol. 16, no. 4, pp. 609–618, 24 2018.
